Impact of availability of CD4 assays and ART for women with CD4≤350/µl.

aResults highlight that providing CD4 assays for all women identified as HIV-infected, and ART for all women with CD4≤350/µl would lead to projected MTCT risks under the 2009 sdNVP-based program (56% uptake, sdNVP strategy: 11.4% at birth and 15.8% at 12 mo) comparable to if Option A were implemented at 56% uptake without increased CD4 and ART availability (56% uptake, Option A strategy: 12.0% at birth and 15.6% at 12 mo).